Azithromycin: Effective Single-Dose Treatment for Bacterial Infections
| Product dosage: 0.25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.54 | $48.22 (0%) | 🛒 Add to cart |
| 120 | $0.49 | $64.29 $59.27 (8%) | 🛒 Add to cart |
| 180 | $0.46 | $96.43 $83.38 (14%) | 🛒 Add to cart |
| 270 | $0.44 | $144.65 $117.53 (19%) | 🛒 Add to cart |
| 360 | $0.42
Best per pill | $192.87 $152.69 (21%) | 🛒 Add to cart |
Synonyms | |||
Azithromycin is a macrolide antibiotic widely prescribed for its broad-spectrum efficacy against common bacterial pathogens. It functions by inhibiting bacterial protein synthesis, effectively stopping the growth and spread of susceptible organisms. With a convenient dosing regimen and proven clinical success, it remains a first-line choice for respiratory, skin, and sexually transmitted infections. Its extended half-life allows for shorter treatment courses, enhancing patient adherence and reducing the risk of resistance development.
Features
- Active ingredient: Azithromycin dihydrate
- Available in 250 mg and 500 mg oral tablets
- Extended half-life of approximately 68 hours
- Broad-spectrum activity against Gram-positive and Gram-negative bacteria
- Acid-stable formulation for reliable oral absorption
- Once-daily dosing convenience
Benefits
- Rapid onset of action with symptomatic improvement often within 48 hours
- Short treatment duration (typically 3–5 days) due to prolonged tissue penetration
- High efficacy rates for respiratory tract infections, including community-acquired pneumonia
- Effective single-dose regimen for uncomplicated genital infections
- Lower incidence of gastrointestinal side effects compared to other macrolides
- Suitable for patients with penicillin allergy (non–type I hypersensitivity)
Common use
Azithromycin is indicated for the treatment of mild to moderate infections caused by susceptible strains of microorganisms. Common applications include acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD), acute bacterial sinusitis, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, urethritis and cervicitis, and genital ulcer disease. Off-label uses may include prevention of Mycobacterium avium complex in immunocompromised patients and treatment of certain gastrointestinal infections.
Dosage and direction
For most indications in adults: 500 mg as a single dose on the first day, followed by 250 mg once daily on days 2 through 5. Alternative regimen: 500 mg once daily for 3 days. For sexually transmitted infections: single 1 g dose. Pediatric dosing is weight-based (10 mg/kg on day 1, then 5 mg/kg on days 2–5, maximum 500 mg/day). Administer at least 1 hour before or 2 hours after meals for optimal absorption. Complete the full prescribed course even if symptoms improve earlier.
Precautions
Use with caution in patients with hepatic impairment; consider monitoring liver function tests. May prolong QT interval; avoid in patients with known QT prolongation, history of torsades de pointes, or concurrent use of other QT-prolonging drugs. Use during pregnancy only if clearly needed (Category B). Excreted in human milk; caution advised during breastfeeding. Superinfection with resistant organisms may occur. Not recommended for treatment of severe pneumonia requiring hospitalization.
Contraindications
Known hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic. Contraindicated in patients with history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use. Avoid use in patients with known QT prolongation or ventricular arrhythmias. Not recommended for patients with myasthenia gravis due to risk of symptom exacerbation.
Possible side effect
Common (≥1%): diarrhea, nausea, abdominal pain, vomiting. Less common: headache, dizziness, rash, elevated liver enzymes. Rare but serious: QT prolongation, torsades de pointes, hepatotoxicity, Clostridioides difficile-associated diarrhea, allergic reactions including anaphylaxis, hearing impairment. Discontinue immediately if signs of hepatitis, arrhythmia, or severe skin reactions occur.
Drug interaction
Significant interactions with warfarin (monitor INR), digoxin (monitor levels), cyclosporine (monitor levels), and ergot derivatives (contraindicated). May increase concentrations of drugs metabolized by CYP3A4. Concurrent use with other QT-prolonging agents (antiarrhythmics, antipsychotics, fluoroquinolones) increases arrhythmia risk. Antacids containing aluminum or magnesium may reduce absorption; administer至少 2 hours apart.
Missed dose
Take the missed dose as soon as remembered. If it is almost time for the next dose, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed one. Maintain the prescribed interval between doses to ensure consistent therapeutic levels.
Overdose
Symptoms may include severe nausea, vomiting, diarrhea, and temporary hearing loss. Management is supportive; gastric lavage may be considered if presented early. No specific antidote exists. Hemodialysis is not effective due to high protein binding and extensive tissue distribution. Monitor ECG for QT prolongation and provide symptomatic treatment for gastrointestinal distress.
Storage
Store at controlled room temperature (20–25°C or 68–77°F). Protect from light and moisture. Keep in original container with tight closure. Do not transfer to other containers. Keep out of reach of children and pets. Do not use after expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional for diagnosis and treatment recommendations. Dosage and indications may vary based on individual patient factors, local guidelines, and antimicrobial resistance patterns. Not all possible uses, precautions, or interactions are listed here.
Reviews
Clinical studies demonstrate azithromycin’s efficacy with cure rates of 85–95% for respiratory infections and 95–98% for chlamydial infections. Meta-analyses confirm superior tolerability profile compared to erythromycin. Post-marketing surveillance shows favorable safety profile with serious adverse events occurring in <0.1% of patients. Healthcare providers consistently report high patient satisfaction due to convenient dosing and rapid symptom resolution.